WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:WAVE Life Sciences Ltd (WVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8113
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company’s pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and antisense, among others. It utilizes its proprietary synthetic chemistry platform to design, develop and commercialize nucleic acid therapeutics. WAVE Life Sciences’ stereopure nucleic acid therapeutics are developed to affect the production of disease associated proteins and target rare genetic diseases. The company controls the orientation of the chemical linkages. It has its operations in Singapore, the US, Japan, the UK and Ireland. WAVE Life Sciences is headquartered in Singapore.

WAVE Life Sciences Ltd (WVE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
WaVE Life Sciences Raises USD66 Million in Series B Financing Round 11
WaVe Life Sciences Raises USD18 Million in Series A Financing 13
Partnerships 14
WAVE Life Sciences and Deep Genomics Enter into Agreement 14
ReadCoor and WAVE Life Sciences Enter into Research Agreement 15
Wave Life Sciences Enters into Research Agreement with University of Massachusetts Medical School 16
nLife Therapeutics Enters into Research Agreement with WAVE Life Sciences 17
Wave Life Sciences Enters into Research Agreement with University of Dundee 18
Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 19
Wave Life Sciences Enters into Research Agreement with Children’s Hospital of Philadelphia 21
Wave Life Sciences Enters into Research Agreement with University of Oxford 22
Licensing Agreements 23
Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 23
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 25
Equity Offering 26
WAVE Life Sciences Prices Public Offering of Shares for USD100 Million 26
Wave Life Sciences Completes IPO For USD111.9 Million 28
WAVE Life Sciences Ltd – Key Competitors 30
WAVE Life Sciences Ltd – Key Employees 31
WAVE Life Sciences Ltd – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 09, 2018: Wave Life Sciences reports second quarter 2018 financial results and provides business update 33
May 09, 2018: Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update 36
Mar 12, 2018: Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 38
Aug 09, 2017: Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update 42
May 10, 2017: WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update 44
Mar 16, 2017: WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update 46
Product News 48
Oct 10, 2018: Wave Life Sciences plans to design treatments for genetic eye diseases 48
01/06/2017: WAVE Life Sciences Provides Update on Duchenne Muscular Dystrophy Program WVE-210201 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WAVE Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
WaVE Life Sciences Raises USD66 Million in Series B Financing Round 11
WaVe Life Sciences Raises USD18 Million in Series A Financing 13
WAVE Life Sciences and Deep Genomics Enter into Agreement 14
ReadCoor and WAVE Life Sciences Enter into Research Agreement 15
Wave Life Sciences Enters into Research Agreement with University of Massachusetts Medical School 16
nLife Therapeutics Enters into Research Agreement with WAVE Life Sciences 17
Wave Life Sciences Enters into Research Agreement with University of Dundee 18
Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 19
Wave Life Sciences Enters into Research Agreement with Children’s Hospital of Philadelphia 21
Wave Life Sciences Enters into Research Agreement with University of Oxford 22
Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 23
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 25
WAVE Life Sciences Prices Public Offering of Shares for USD100 Million 26
Wave Life Sciences Completes IPO For USD111.9 Million 28
WAVE Life Sciences Ltd, Key Competitors 30
WAVE Life Sciences Ltd, Key Employees 31
WAVE Life Sciences Ltd, Subsidiaries 32

List of Figures
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cross Country Healthcare Inc (CCRN):企業の財務・戦略的SWOT分析
    Cross Country Healthcare Inc (CCRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • ASML Holding N.V.:企業の戦略・SWOT・財務情報
    ASML Holding N.V. - Strategy, SWOT and Corporate Finance Report Summary ASML Holding N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SeraCare Life Sciences, Inc.-医療機器分野:企業M&A・提携分析
    Summary SeraCare Life Sciences, Inc. (SeraCare) carries out the discovery, development, manufacture and supply of disease-state specimens and tissues for research and development, processed biological materials, immunoassay reagents and quality control products and technologies. Its major products i …
  • Douglas Holding AG:戦略・SWOT・企業財務分析
    Douglas Holding AG - Strategy, SWOT and Corporate Finance Report Summary Douglas Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Statkraft AS:企業の戦略・SWOT・財務分析
    Statkraft AS - Strategy, SWOT and Corporate Finance Report Summary Statkraft AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Valmieras Stikla Skiedra AS:企業の戦略・SWOT・財務情報
    Valmieras Stikla Skiedra AS - Strategy, SWOT and Corporate Finance Report Summary Valmieras Stikla Skiedra AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Power Assets Holdings Ltd (6):電力:M&Aディール及び事業提携情報
    Summary Power Assets Holdings Limited (Power Assets) a subsidiary of CK Infrastructure Holdings Limited, is an investment holding company. The company through its subsidiaries, joint ventures, and affiliates, invests in power and utility-related businesses. The company has interests in electricity g …
  • Gulf Power Co:電力:M&Aディール及び事業提携情報
    Summary Gulf Power Co (Gulf Power), a subsidiary of Southern Company, is an integrated energy utility. It generates, procures, transmits, and distributes electricity. The company produces electricity using coal and gas sources. Through agreements with industrial, commercial, and qualifying facilitie …
  • Integer Holdings Corp (GB):企業の財務・戦略的SWOT分析
    Summary Integer Holdings Corp (Integrated Holdings), formerly Greatbatch Inc is a medical device outsource manufacturer that designs and develops medical devices and power solutions for the medical and non-medical markets. The company offers products such as arthroscopic devices and components, lapa …
  • Oneok Inc (OKE):企業の財務・戦略的SWOT分析
    Oneok Inc (OKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ypsomed Holding AG (YPSN):企業の製品パイプライン分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company that designs, develops and manufactures injection and infusion systems for self-medication and offers related services. It offers autoinjectors, dual chamber pens, and pen injectors. The company also offers services ranging from design …
  • nLife Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops proprietary neuronal specific oligonucleotides as therapeutic agents for the treatment of central nervous system disorders. Its lead candidate NLF-PD-1233 is a first in class oligonucleotide …
  • Applied Materials Inc (AMAT):企業の財務・戦略的SWOT分析
    Applied Materials Inc (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Wilbur-Ellis Company:企業の戦略・SWOT・財務情報
    Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report Summary Wilbur-Ellis Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Orica Ltd:企業の戦略・SWOT・財務情報
    Orica Ltd - Strategy, SWOT and Corporate Finance Report Summary Orica Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Renaissance Oil Corp (ROE):石油・ガス:M&Aディール及び事業提携情報
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • China National Petroleum Corporation:企業の戦略・SWOT・財務情報
    China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Greencore Group Plc:企業のM&A・事業提携・投資動向
    Greencore Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Greencore Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • HEICO Corporation:企業の戦略・SWOT・財務情報
    HEICO Corporation - Strategy, SWOT and Corporate Finance Report Summary HEICO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Henry Ford Health System:企業の戦略的SWOT分析
    Henry Ford Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆